Please use this identifier to cite or link to this item: https://accedacris.ulpgc.es/jspui/handle/10553/158860
Title: Building a Robust Investigator‐Initiated Platform: The I‐CARE Experience
Authors: Kirchgesner, Julien
Beaugerie, Laurent
Baumann, Cédric
Baert, Filip
Rahier, Jean‐François
Bergemalm, Daniel
Cañete, Fiorella
Caron, Bénédicte
Cossignani, Marta
Dias, Sandra
Farkas, Klaudia
Girod, Parker
Goren, Idan
Holvoet, Tom
Krasz, Susanne
Kumar, Aditi
Rimmer, Peter
Sheridan, Juliette
Thut, Jessica
Uzzan, Mathieu
Viazis, Nikos
Weimers, Petra
Zagórowicz, Edyta
Buisson, Anne
Avedano, Luisa
Rousseau, Helene
Peyrin‐Biroulet, Laurent
Sebastian, Shaji
Ceballos Santos, Daniel Sebastián 
UNESCO Clasification: 32 Ciencias médicas
3201 Ciencias clínicas
320503 Gastroenterología
Issue Date: 2026
Journal: Clinical pharmacology and therapeutics 
Abstract: Investigator-initiated studies that include information collected by patients are rising, but limited data is available on patient and investigator experience in this setting. The I-CARE cohort included patients with inflammatory bowel disease (IBD) monthly collecting clinical information in 15 countries for up to 6 years. We describe patients and investigators' involvement in I-CARE and identify predictors of early withdrawal due to patient non-engagement. Patients' characteristics according to the number of electronic Patient-reported outcomes (ePRO) completed during follow-up were assessed. Predictors of early withdrawal due to patient non-engagement were identified using logistic regression. The coding of outcomes reported by patients and corrections by investigators on patients' ePROs were assessed. Among 12,846 patients included by 502 investigators, 79.3% and 77.3% filled more than one ePRO and at least one ePRO within 6 months before the study end date, respectively. All ePROs were completed in 72.8% and 56.4% of patients during year 1 and 3, respectively. Male gender, younger age (< 20), being unemployed or a student, and no previous history of abdominal surgery were associated with early withdrawal. Investigators corrected 52.5% of cancer or dysplasia reported by patients compared to 10% of serious infections. Investigators added or removed a treatment sequence in 19.6% of the 6708 patients treated with biologics. These results highlight the implication of patients in research and the importance of data validation by investigators alongside the challenge and potential of collecting medical data from patients. These findings can inform similar future initiatives in other diseases.
URI: https://accedacris.ulpgc.es/jspui/handle/10553/158860
ISSN: 0009-9236
DOI: 10.1002/cpt.70231
Source: Clinical pharmacology and therapeutics, [ISSN 0009-9236], 2026
Appears in Collections:Artículo de prensa
Show full item record

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.